[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534312":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"National Research Center for Hematology, Russia","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MRD-positive with Target therapy","EXPERIMENTAL","MRD-positive patients after induction therapy in target therapy group (for B-ALL- blinatumomab, for T-ALL - venetoclax+ChT)",[13],"Drug: blinatumomab for B-ALL, venetoclax for T-ALL",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","blinatumomab for B-ALL, venetoclax for T-ALL","MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Elena Parovichnikova, MD, PhD","National Research Medical Center for Hematology","STUDY_DIRECTOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Olga Aleshina, MD, PhD","CONTACT","+79629745058","dr.gavrilina@mail.ru",[33],{"facility":34,"status":35,"city":36,"state":20,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Olga Aleshina","RECRUITING","Moscow","Russia","RU",{"type":40,"coordinates":41},"Point",[42,43],37.61781,55.75204,{"lat":43,"lon":42},[46],{"name":34,"role":29,"phone":30,"phoneExt":20,"email":20},{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100534312","mrd-associated-non-intensive-but-non-interruptive-treatment-of-ph-negative-acute-lymphoblastic-leukemia-adult-patients-100534312",false,"NCT06237192","MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients","Multicenter Prospective Study of Safety and Efficacy MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients","Inclusion Criteria:\n\n• age 18-55 years old of patient,\n\n\\- Clinical diagnosis of non-treated Ph-negative ALL\n\nExclusion Criteria:\n\n• age more than 55 years old,\n\n* Clinical diagnosis of Ph-positive ALL\n* Clinical diagnosis of relapsed\u002Frefractory ALL,","ALL","18 Years","55 Years",{"count":60,"type":61},200,"ESTIMATED","INTERVENTIONAL",[64],"NA","Non-intensive But Non-interruptive Treatment based on previously study RALL-2016 of Adult Ph-negative Acute Lymphoblastic Leukemia: No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL patients in complete remission (CR) with MRD-positive status after 2nd induction receive consolidation 1-3 with venetoclax (56 days), and B-ALL patients in complete remission (CR) with MRD-positive status after 2nd induction receive 1 consolidation with blinatumomab. After that consolidation bone samples are collected and tested for MRD and patients will continue therapy by protocol without HSCT if MRD-negative (by flow cytometry by aberrant immunophenotype in a centralized lab) status was achieved.",[67],"Precursor Cell Lymphoblastic Leukemia-Lymphoma","2024-01-31",{"date":70,"type":71},"2024-02-01","ACTUAL",{"date":73,"type":71},"2023-04-01",{"date":75,"type":61},"2027-09-01",{"name":5,"class":6},1]